Drug intelligence / Profile preview

BR1019A + BR1019B

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

**BR1019A + BR1019B** is an investigational combination therapy developed for the treatment of essential hypertension and type 2 diabetes mellitus. It is currently under evaluation in phase 3 clinical trials. The precise mechanism of action and the molecular identities of BR1019A and BR1019B have not been publicly disclosed. This therapy is being developed and studied by Boryung Pharmaceutical. The combination is administered as an oral therapy and is designed to address both glucose and blood pressure control in affected patients[1][2][3][5][7][8].

Beyond the preview

Go deeper on BR1019A + BR1019B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1019A + BR1019B.

Explore the full profile